(CNTA) Centessa Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.192m USD | Total Return: 203.9% in 12m

Stock Medicines, Treatments, Neurological, Neurodegenerative, Psychiatric
Total Rating 39
Safety 21
Buy Signal 0.11
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 4,192m
Avg Trading Vol: 39.8M USD
ATR: 5.97%
Peers RS (IBD): 85.3
Risk 5d forecast
Volatility182%
Rel. Tail Risk-10.8%
Reward TTM
Sharpe Ratio1.68
Alpha160.90
Character TTM
Beta0.502
Beta Downside0.762
Drawdowns 3y
Max DD43.72%
CAGR/Max DD2.76
Risks
Technicals: choppy
Description: CNTA Centessa Pharmaceuticals

Centessa Pharmaceuticals plc (CNTA) is a clinical-stage pharmaceutical company founded in 2020 and based in the United Kingdom. As a biotechnology firm, it focuses on discovering and developing new medicines.

The companys primary clinical program is ORX750, an oral OX2R agonist currently in Phase 2a trials for idiopathic hypersomnia and narcolepsy types 1 and 2. This therapeutic area targets sleep disorders, a significant market within CNS pharmaceuticals. CNTA also develops ORX142 for neurological and neurodegenerative disorders and ORX489 for neuropsychiatric conditions. Additionally, Centessa utilizes its LockBody platform, designed to direct immune effector function to tumor microenvironments, indicating an interest in oncology applications.

Further research on ValueRay can provide deeper insights into CNTAs pipeline and market position.

Headlines to Watch Out For
  • ORX750 Phase 2a results dictate stock movement
  • Regulatory approval of lead drug candidate crucial for revenue
  • Clinical trial success for ORX142 impacts future pipeline
  • LockBody platform development offers long-term growth potential
Piotroski VR‑10 (Strict) 1.0
Net Income: -242.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.40 > 0.02 and ΔFCF/TA -19.57 > 1.0
NWC/Revenue: 1.75k% < 20% (prev 7.91k%; Δ -6.16k% < -1%)
CFO/TA -0.40 > 3% & CFO -180.8m > Net Income -242.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.57 > 1.5 & < 3
Outstanding Shares: last quarter (134.2m) vs 12m ago 15.41% < -2%
Gross Margin: 94.22% > 18% (prev 0.86%; Δ 9.34k% > 0.5%)
Asset Turnover: 3.02% > 50% (prev 1.12%; Δ 1.89% > 0%)
Interest Coverage Ratio: -20.50 > 6 (EBITDA TTM -227.3m / Interest Expense TTM 11.1m)
Altman Z'' -14.96
A: 0.62 (Total Current Assets 307.7m - Total Current Liabilities 29.1m) / Total Assets 448.3m
B: -2.50 (Retained Earnings -1.12b / Total Assets 448.3m)
C: -0.43 (EBIT TTM -228.2m / Avg Total Assets 529.0m)
D: -7.61 (Book Value of Equity -1.12b / Total Liabilities 146.7m)
Altman-Z'' Score: -14.96 = D
Beneish M 0.31
DSRI: 0.56 (Receivables 52.2m/40.0m, Revenue 16.0m/6.85m)
GMI: 0.91 (GM 94.22% / 85.95%)
AQI: 6.01 (AQ_t 0.29 / AQ_t-1 0.05)
SGI: 2.33 (Revenue 16.0m / 6.85m)
TATA: -0.14 (NI -242.7m - CFO -180.8m) / TA 448.3m)
Beneish M-Score: 0.31 (Cap -4..+1) = D
What is the price of CNTA shares? As of April 05, 2026, the stock is trading at USD 39.72 with a total of 47,690,198 shares traded.
Over the past week, the price has changed by +38.29%, over one month by +51.49%, over three months by +72.42% and over the past year by +203.91%.
Is CNTA a buy, sell or hold? Centessa Pharmaceuticals has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CNTA.
  • StrongBuy: 7
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CNTA price?
Wallstreet Target Price 40.4 1.7%
Analysts Target Price 40.4 1.7%
CNTA Fundamental Data Overview as of 05 April 2026
P/S = 279.4916
P/B = 13.2638
Revenue TTM = 16.0m USD
EBIT TTM = -228.2m USD
EBITDA TTM = -227.3m USD
Long Term Debt = 109.8m USD (from longTermDebt, last quarter)
Short Term Debt = 684k USD (from shortTermDebt, last quarter)
Debt = 118.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 67.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.06b USD (4.19b + Debt 118.3m - CCE 246.2m)
Interest Coverage Ratio = -20.50 (Ebit TTM -228.2m / Interest Expense TTM 11.1m)
EV/FCF = -22.43x (Enterprise Value 4.06b / FCF TTM -181.2m)
FCF Yield = -4.46% (FCF TTM -181.2m / Enterprise Value 4.06b)
 FCF Margin = -1.14k% (FCF TTM -181.2m / Revenue TTM 16.0m)
 Net Margin = -1.52k% (Net Income TTM -242.7m / Revenue TTM 16.0m)
 Gross Margin = 94.22% ((Revenue TTM 16.0m - Cost of Revenue TTM 923k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 9.07 (Enterprise Value 4.06b / Total Assets 448.3m)
Interest Expense / Debt = 2.44% (Interest Expense 2.89m / Debt 118.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -180.3m (EBIT -228.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.57 (Total Current Assets 307.7m / Total Current Liabilities 29.1m)
Debt / Equity = 0.39 (Debt 118.3m / totalStockholderEquity, last quarter 301.6m)
 Debt / EBITDA = -0.30 (negative EBITDA) (Net Debt 67.4m / EBITDA -227.3m)
 Debt / FCF = -0.37 (negative FCF - burning cash) (Net Debt 67.4m / FCF TTM -181.2m)
 Total Stockholder Equity = 358.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.88% (Net Income -242.7m / Total Assets 448.3m)
RoE = -67.68% (Net Income TTM -242.7m / Total Stockholder Equity 358.6m)
RoCE = -48.72% (EBIT -228.2m / Capital Employed (Equity 358.6m + L.T.Debt 109.8m))
 RoIC = -38.52% (negative operating profit) (NOPAT -180.3m / Invested Capital 468.0m)
 WACC = 7.59% (E(4.19b)/V(4.31b) * Re(7.75%) + D(118.3m)/V(4.31b) * Rd(2.44%) * (1-Tc(0.21)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 17.05%
 [DCF] Fair Price = unknown (Cash Flow -181.2m)
 EPS Correlation: 59.16 | EPS CAGR: 50.66% | SUE: 1.71 | # QB: 2
Revenue Correlation: 32.10 | Revenue CAGR: 0.0% | SUE: -0.26 | # QB: 0
EPS next Year (2026-12-31): EPS=-1.64 | Chg7d=+0.000 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=-21.9% | Growth Revenue=-100.0%
External Resources
Dataroma Stockcircle